Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1293-1295

  Charpentier, Charlotte ^a,b   Roquebert, Bénédicte ^a,b   Delelis, Olivier ^c   Larrouy, Lucile ^a,b   Matheron, Sophie ^a,b   Tubiana, Roland ^d   Karmochkine, Marina ^e   Duval, Xavier ^a   Chêne, Geneviève ^f   Storto, Alexandre ^a,b   Collin, Gilles ^a,b   Bénard, Antoine ^f   Damond, Florence ^a,b   Mouscadet, Jean François ^c   Brun Vézinet, Françoise ^a,b   Descamps, Diane ^a,b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Ecole Normale Superieure de Cachan   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; INTEGRASE; LAMIVUDINE; PROTEINASE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG TREATMENT FAILURE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; PRIORITY JOURNAL; VIRAL GENETICS; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 79952344732     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00942-10     Document Type: Article

References (13)

1. Clavel, F. 2009. HIV resistance to raltegravir. Eur. J. Med. Res. 14:47-54.
2. Damond, F., et al. 2005. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay. J. Clin. Microbiol. 43:4234-4236.
3. Fransen, S., et al. 2009. Longitudinal phenotypic analysis of raltegravir-resistant viruses during virologic failure. Antimicrob. Agents Chemother. 53:4522-4524.
4. Gao, F., et al. 1994. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J. Virol. 68:7433-7447. (Pubitemid 24328799)
5. Garrett, N., et al. 2008. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS 22:1091-1092. (Pubitemid 351769751)
6. Hatano, H., et al. 2010. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 54:389-393.
7. Lataillade, M., J. Chiarella, and M. J. Kozal. 2007. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir. Ther. 12:563-570.
8. Malet, I., et al. 2009. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J. Antimicrob. Chemother. 63:795-804.
9. Miller, M. D., et al. 2008. Longitudinal analysis of resistance to the HIV-1 integrase inhibitor raltegravir: results from P005 a phase II study in treatment- experienced patients. Antivir. Ther. 13(Suppl. 3):A8.
10. Pieniazek, D., et al. 1999. Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. AIDS Res. Hum. Retroviruses 15:603-608.
11. Roquebert, B., et al. 2008. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS 22:2045-2046.
12. Roquebert, B., et al. 2008. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J. Antimicrob. Chemother. 62:914-920.
13. Salgado, M., et al. 2009. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J. Clin. Virol. 46:173-175.